GlassScriptPhysician profile
Ruchi Yadav
NPI 1659905644
$4,012.82
in general payments reported to CMS, 2019-2025
37 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,506 · 2024: $2,345 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.52 |
| Education | $655.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $453.64 | 2023-2024 | Erleada, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $422.45 | 2023-2025 | Tagrisso, Andexxa, Lynparza |
| Seagen INC. | $311.67 | 2023 | Tukysa, Adcetris, Padcev |
| Alexion Pharmaceuticals, INC. | $291.28 | 2023-2024 | Ultomiris, Soliris |
| Celgene Corporation | $225.85 | 2023-2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $206.19 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.48 | 2023-2024 | Ninlaro, Iclusig |
| Novartis Pharmaceuticals Corporation | $147.22 | 2024-2025 | |
| Gilead Sciences, INC. | $142.71 | 2023-2024 | |
| Abbvie INC. | $117.43 | 2024-2025 | |
| Puma Biotechnology, INC. | $113.66 | 2023-2024 | |
| Incyte Corporation | $111.13 | 2023-2024 | Jakafi |
| Lilly USA, LLC | $102.25 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $100.41 | 2023-2024 | Krazati |
| Merck Sharp & Dohme LLC | $98.44 | 2023-2024 | Keytruda |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $91.30 | 2023-2024 | Balfaxar, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Panzyga |
| Stemline Therapeutics INC. | $89.24 | 2024 | Orserdu |
| Eisai INC. | $76.34 | 2023-2024 | |
| Taiho Oncology, INC. | $74.63 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $71.80 | 2023-2024 | Libtayo |
| Astellas Pharma US INC | $69.99 | 2024 | |
| Emd Serono, INC. | $53.66 | 2023 | Tepmetko |
| G1 Therapeutics, INC. | $47.91 | 2023 | Cosela |
| Glaxosmithkline, LLC. | $45.23 | 2023-2024 | Ojjaara, Shingrix |
| Pharmaessentia USA Corporation | $40.87 | 2024 | Besremi |
| Exelixis INC. | $33.17 | 2023 | Cabometyx |
| Sobi, INC | $32.87 | 2024 | |
| Genmab U.S., INC. | $32.14 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $30.91 | 2024 | Xarelto |
| Genzyme Corporation | $30.80 | 2024 | |
| Array Biopharma INC | $28.33 | 2024 | Braftovi, Lorbrena, Xalkori |
| Coherus Oncology, INC. | $28.21 | 2023 | |
| Sumitomo Pharma America, INC. | $25.78 | 2023 | Orgovyx |
| Jazz Pharmaceuticals INC. | $25.35 | 2024 | |
| Rigel Pharmaceuticals, INC. | $24.52 | 2023 | Tavalisse, Rezlidhia |
| Amgen INC. | $22.16 | 2024 | |
| Tactile Systems Technology INC | $18.80 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.